Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Receivables (2017 - 2025)

Sutro Biopharma's Receivables history spans 9 years, with the latest figure at $3.9 million for Q3 2025.

  • For Q3 2025, Receivables fell 41.07% year-over-year to $3.9 million; the TTM value through Sep 2025 reached $3.9 million, down 41.07%, while the annual FY2024 figure was $8.6 million, 76.12% down from the prior year.
  • Receivables for Q3 2025 was $3.9 million at Sutro Biopharma, down from $8.0 million in the prior quarter.
  • Across five years, Receivables topped out at $97.7 million in Q2 2022 and bottomed at $3.9 million in Q3 2025.
  • The 5-year median for Receivables is $10.0 million (2023), against an average of $16.9 million.
  • The largest annual shift saw Receivables surged 966.28% in 2022 before it crashed 89.76% in 2023.
  • A 5-year view of Receivables shows it stood at $12.5 million in 2021, then plummeted by 42.81% to $7.1 million in 2022, then skyrocketed by 406.57% to $36.1 million in 2023, then crashed by 76.12% to $8.6 million in 2024, then tumbled by 54.48% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Receivables are $3.9 million (Q3 2025), $8.0 million (Q2 2025), and $13.6 million (Q1 2025).